ONO-7702/7703-03:NO-7702/ONO-7703 Phase2 Study
Phase 2
- Conditions
- Radically unresectable BRAF V600-mutant thyroid cancer
- Registration Number
- JPRN-jRCT2011200018
- Lead Sponsor
- Hirashima Yoshinori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
1. Age >= 20 years
2. histologically diagnosed radically unresectable locally advanced or distant metastatic thyroid cancerars
3. positive BRAF V600 mutation
4. ECOG Performance Status of 0 or 1
5. Able to swallow, ingest, and absorb oral drugs
Exclusion Criteria
1. Prior treatment with any RAF inhibitor or MEK inhibitor
2. symptomatic brain metastasis, leptomeningeal disease, or other active central nervous system (CNS) metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective Response rate (central review)
- Secondary Outcome Measures
Name Time Method